ClinicalTrials.gg
CompletedNCT00504881Updated Apr 3, 2018Results posted

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

A Phase 3 interventional study of Placebo and Brivaracetam in Epilepsy, sponsored by UCB Pharma SA. Completed at 63 sites in 15 countries. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-04-03.

Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
16 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
5th of 34
480 · median 94
Started
2007
with 2 others
Phase 3
21 of 34
1 open now
Registered
10th of 34
by date
Lead sponsor
5 of 34
UCB Pharma SA

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 5th largest by enrollment, is one of 3 that started in 2007, is one of 21 in phase 3, and was the 10th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Partial Onset Seizures
04

Who can participate

Ages eligible
16 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects were aged from 16 to 70 years, inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted
  • Subjects had well-characterized localization-related Epilepsy or generalized Epilepsy according to the International League Against Epilepsy (ILAE) classification
  • For subjects suffering from localization-related Epilepsy: subjects had at least 2 Partial-Onset Seizures (POSs) whether or not secondarily generalized per month during the 3 months preceding Visit 1 according to the ILAE classification
  • For subjects suffering from localization-related Epilepsy: subjects had at least 4 Partial-Onset Seizures (POSs) whether or not secondarily generalized during the 4-week Baseline Period according to the ILAE classification
  • For subjects suffering from generalized Epilepsy: subjects had at least 2 Type II-seizure days per month during the 3 months preceding Visit 1 according to the ILAE classification
  • For subjects suffering from generalized Epilepsy: subjects had at least 4 Type II-seizure days during the 4 week Baseline Period according to the ILAE classification
  • Subjects were uncontrolled while treated by 1 to 3 permitted concomitant Antiepileptic Drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED

Exclusion criteria

Exclusion Criteria:

  • For subjects who suffered from localization-related Epilepsy: history or presence of Seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 2 or occurring only as Type IA non-motor
  • Subjects with a history or presence of Status Epilepticus during the year preceding Visit 1 or during Baseline
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
480 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching Placebo tablets administered twice a day

    Drug: Placebo

  • Experimental
    Brivaracetam

    A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day

    Drug: Brivaracetam

Interventions

  • DrugPlacebo

    Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period

  • Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: Week 2 to the end of the Treatment Period (Week 16)

  2. Partial Onset Seizure (Type I) Frequency Per Week Over the 16-week Treatment Period

    Partial (Type I) seizures can be classified into one of the following three groups: * Simple partial seizures * Complex partial seizures * Partial seizures evolving to generalized tonic-clonic convulsions. Partial Onset Seizure (POS) frequency per week over the Treatment Period (TP) was calculated as: (Total Type I seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

    Time frame: Baseline (Week 0) to the end of the Treatment Period (Week 16)

Secondary outcomes

  1. Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 16-week Treatment Period

    The responder rate was presented as the percentage of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in Partial Onset Seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders.

    Time frame: Baseline (Week 0) to the end of Treatment Period (Week 16)

  2. Seizure Frequency (All Seizure Types) Per Week Over the 16-week Treatment Period

    There are three different types of seizures: * Type I: Partial seizures * Type II: Generalized seizures * Type III: Unclassified epileptic seizures. All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

    Time frame: Baseline (Week 0) to the end of Treatment Period (Week 16)

  3. Percent Change From Baseline to the 16-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week

    Percent change from Baseline was calculated as percent reduction by: (weekly seizure frequency Baseline - weekly seizure frequency Treatment)\*100/(weekly seizure frequency Baseline). A negative value in percent Change from Baseline indicates an improvement from Baseline. The higher the negative values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline.

    Time frame: Baseline (Week 0) to end of Treatment Period (Week 16)

  4. Categorized Response From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 16-week Treatment Period

    Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: \<-25 %, -25 % to \<25 %, 25 % to \<50 %, 50 % to \<75 %, 75 % to \<100 %, and 100 %. Subjects having zero for Baseline seizure frequency per week were classified in the \<-25 % category.

    Time frame: Baseline to 16-week Treatment Period

  5. Seizure Freedom Rate (All Seizure Types) Over the 16-week Treatment Period

    Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as: (total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)

    Time frame: Baseline (Week 0) to the end of Treatment Period (Week 16)

  6. Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 16-week Treatment Period

    The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.

    Time frame: Baseline to 16-week Treatment Period

  7. Time to First Type I Seizure During the 16-week Treatment Period

    Time to first Type I seizure during the 16-week Treatment Period was measured in days.

    Time frame: Baseline to 16-week Treatment Period

  8. Time to Fifth Type I Seizure During the 16-week Treatment Period

    Time to fifth Type I seizure during the 16-week Treatment Period was measured in days.

    Time frame: Baseline to 16-week Treatment Period

  9. Time to Tenth Type I Seizure During Treatment Period

    Time to tenth Type I seizure during the 16-week Treatment Period was measured in days.

    Time frame: Baseline to 16-week Treatment Period

  10. Change From Baseline to the 16-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

  11. Change From Baseline to the 16-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

  12. Change From Baseline to the 16-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

  13. Change From Baseline to the 16-week Treatment Period in Hospital Anxiety Score

    The Hospital Anxiety and Depression Scale (HADS) was used to evaluate Anxiety and Depression. The HADS was developed as a self-administered scale to assess the presence and severity of Anxiety and Depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 (higher scores indicating greater problems). A negative value in change from Baseline indicates an improvement from Baseline.

    Time frame: Baseline to 16-week Treatment Period

  14. Change From Baseline to the 16-week Treatment Period in Hospital Depression Score

    The Hospital Anxiety and Depression Scale (HADS) was used to evaluate Anxiety and Depression.The HADS was developed as a self-administered scale to assess the presence and severity of Anxiety and Depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 (higher scores indicating greater problems). A negative value in change from Baseline indicates an improvement from Baseline.

    Time frame: Baseline to 16-week Treatment Period

  15. Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit

    The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7= Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?'

    Time frame: Baseline to last visit or early discontinuation visit in the 16-week Treatment Period

  16. Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit

    The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7= Marked improvement) with the start of the study medication as the reference time point. The Investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.'

    Time frame: Baseline to Last Visit or Early Discontinuation Visit in the 16-week Treatment Period

  17. Change From Baseline to the 16-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

  18. Change From Baseline to the 16-week Treatment Period in Emotional Well-being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

  19. Change From Baseline to the 16-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

  20. Change From Baseline to the 16-week Treatment Period in Overall Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

  21. Change From Baseline to the 16-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

    The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

    Time frame: Baseline to 16-week Treatment Period

07

Results

Posted Mar 17, 2017

Participant flow

This multicenter study was conducted in 15 countries. It started in October 2007 and concluded in December 2008.

Participant flow — Overall Study
MilestonePlaceboBrivaracetam
Started121359
Completed111323
Not completed1036
Withdrew: Lack of efficacy15
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject14
Withdrew: Non-compliance10
Withdrew: No birth control01
Withdrew: Safety visit not performed01
Withdrew: Ae, serious fatal01
Withdrew: Sae, non-fatal26
Withdrew: Ae, non-serious non-fatal414
Withdrew: Sae,non-fatal+ae,non-serious non-fatal02
Withdrew: Ae of unknown type10

Outcome measures

PrimaryPercentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period

An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
Week 2 to the end of the Treatment Period (Week 16)
Reported as:
Number · percentage of participants
Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period
percentage of participantsPlaceboBrivaracetam
Percentage of Subjects With at Least One Adverse Event During the 16-week Treatment Period66.166.6
PrimaryPartial Onset Seizure (Type I) Frequency Per Week Over the 16-week Treatment Period

Partial (Type I) seizures can be classified into one of the following three groups: * Simple partial seizures * Complex partial seizures * Partial seizures evolving to generalized tonic-clonic convulsions. Partial Onset Seizure (POS) frequency per week over the Treatment Period (TP) was calculated as: (Total Type I seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

Time frame:
Baseline (Week 0) to the end of the Treatment Period (Week 16)
Reported as:
Median · seizures per week
Partial Onset Seizure (Type I) Frequency Per Week Over the 16-week Treatment Period
seizures per weekPlaceboBrivaracetam
Partial Onset Seizure (Type I) Frequency Per Week Over the 16-week Treatment Period1.86 (1.00 to 3.98)1.74 (0.86 to 4.04)
Statistical analysis
  • Placebo vs Brivaracetam · ANCOVA · p = =0.125 · Percent reduction over placebo: 7.3 · 95% CI -2.2 to 15.9
SecondaryResponder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 16-week Treatment Period

The responder rate was presented as the percentage of responders and non-responders. A subject is a responder, if the subject has at least 50 % reduction in Partial Onset Seizure frequency per week from Baseline to Treatment Period. Subjects with zero seizure frequency per week at Baseline were considered as non-responders.

Time frame:
Baseline (Week 0) to the end of Treatment Period (Week 16)
Reported as:
Number · percentage of participants
Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 16-week Treatment Period
percentage of participantsPlaceboBrivaracetam
Responders16.730.3
Non-Responders83.369.7
SecondarySeizure Frequency (All Seizure Types) Per Week Over the 16-week Treatment Period

There are three different types of seizures: * Type I: Partial seizures * Type II: Generalized seizures * Type III: Unclassified epileptic seizures. All seizure frequency per week over Treatment Period (TP) was calculated as: (Total number of seizures over the TP)\*7/(Total number of days with no missing seizure count in the TP)

Time frame:
Baseline (Week 0) to the end of Treatment Period (Week 16)
Reported as:
Median · number of seizures per week
Seizure Frequency (All Seizure Types) Per Week Over the 16-week Treatment Period
number of seizures per weekPlaceboBrivaracetam
Seizure Frequency (All Seizure Types) Per Week Over the 16-week Treatment Period1.87 (1.00 to 4.59)1.74 (0.86 to 4.04)
SecondaryPercent Change From Baseline to the 16-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week

Percent change from Baseline was calculated as percent reduction by: (weekly seizure frequency Baseline - weekly seizure frequency Treatment)\*100/(weekly seizure frequency Baseline). A negative value in percent Change from Baseline indicates an improvement from Baseline. The higher the negative values for percent change in Partial Onset Seizure (POS) frequency, the higher the improvement from Baseline.

Time frame:
Baseline (Week 0) to end of Treatment Period (Week 16)
Reported as:
Median · percent change
Percent Change From Baseline to the 16-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week
percent changePlaceboBrivaracetam
Percent Change From Baseline to the 16-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week-18.93 (-39.05 to -7.83)-26.92 (-55.98 to 11.44)
SecondaryCategorized Response From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 16-week Treatment Period

Subjects were classified in 1 of the following categories based on their percent reduction from Baseline to Treatment Period in Partial Onset Seizure (POS) frequency per week: \<-25 %, -25 % to \<25 %, 25 % to \<50 %, 50 % to \<75 %, 75 % to \<100 %, and 100 %. Subjects having zero for Baseline seizure frequency per week were classified in the \<-25 % category.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Number · percentage of participants
Categorized Response From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 16-week Treatment Period
percentage of participantsPlaceboBrivaracetam
<- 25 %14.818.3
-25 % to < 25 %44.429.1
25 % to < 50 %24.122.3
50 % to < 75 %13.917.0
75 % to < 100 %2.811.8
100 %01.5
SecondarySeizure Freedom Rate (All Seizure Types) Over the 16-week Treatment Period

Subjects were considered seizure free if their seizure counts for every day over the Treatment Period (TP) was zero and if they did not discontinue before the end of the TP. Seizure freedom rate was calculated as: (total number of seizure - free subjects in treatment group during TP)/(total number of evaluable Intent-To-Treat (ITT) subjects in treatment group)

Time frame:
Baseline (Week 0) to the end of Treatment Period (Week 16)
Reported as:
Number · percentage of participants
Seizure Freedom Rate (All Seizure Types) Over the 16-week Treatment Period
percentage of participantsPlaceboBrivaracetam
Seizure-free01.5
No Seizure but non-completer00
Not Seizure free100.098.5
SecondaryReduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 16-week Treatment Period

The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Number · percentage of participants
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 16-week Treatment Period
percentage of participantsPlaceboBrivaracetam
Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 16-week Treatment Period54.347.9
SecondaryTime to First Type I Seizure During the 16-week Treatment Period

Time to first Type I seizure during the 16-week Treatment Period was measured in days.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Median · days
Time to First Type I Seizure During the 16-week Treatment Period
daysPlaceboBrivaracetam
Time to First Type I Seizure During the 16-week Treatment Period3 (2 to 4)4 (4 to 5)
SecondaryTime to Fifth Type I Seizure During the 16-week Treatment Period

Time to fifth Type I seizure during the 16-week Treatment Period was measured in days.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Median · days
Time to Fifth Type I Seizure During the 16-week Treatment Period
daysPlaceboBrivaracetam
Time to Fifth Type I Seizure During the 16-week Treatment Period14 (11 to 19)18 (16 to 21)
SecondaryTime to Tenth Type I Seizure During Treatment Period

Time to tenth Type I seizure during the 16-week Treatment Period was measured in days.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Median · days
Time to Tenth Type I Seizure During Treatment Period
daysPlaceboBrivaracetam
Time to Tenth Type I Seizure During Treatment Period36 (23 to 44)38 (31 to 43)
SecondaryChange From Baseline to the 16-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score3.04 ± 12.584.22 ± 13.73
SecondaryChange From Baseline to the 16-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score4.66 ± 23.2310.29 ± 21.99
SecondaryChange From Baseline to the 16-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Daily Activities / Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score5.61 ± 21.872.66 ± 23.48
SecondaryChange From Baseline to the 16-week Treatment Period in Hospital Anxiety Score

The Hospital Anxiety and Depression Scale (HADS) was used to evaluate Anxiety and Depression. The HADS was developed as a self-administered scale to assess the presence and severity of Anxiety and Depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 (higher scores indicating greater problems). A negative value in change from Baseline indicates an improvement from Baseline.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Hospital Anxiety Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Hospital Anxiety Score-0.57 ± 3.35-0.85 ± 3.62
SecondaryChange From Baseline to the 16-week Treatment Period in Hospital Depression Score

The Hospital Anxiety and Depression Scale (HADS) was used to evaluate Anxiety and Depression.The HADS was developed as a self-administered scale to assess the presence and severity of Anxiety and Depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 (higher scores indicating greater problems). A negative value in change from Baseline indicates an improvement from Baseline.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Hospital Depression Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Hospital Depression Score0.30 ± 3.08-0.41 ± 3.54
SecondaryPatient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit

The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7= Marked improvement) with the start of the study medication as the reference time point. The subject completed it by answering to the following: 'Overall, has there been a change in your seizures since the start of the study medication?'

Time frame:
Baseline to last visit or early discontinuation visit in the 16-week Treatment Period
Reported as:
Mean · units on a scale
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit
units on a scalePlaceboBrivaracetam
Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit4.73 ± 1.375.07 ± 1.36
SecondaryInvestigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit

The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1= Marked worsening to 7= Marked improvement) with the start of the study medication as the reference time point. The Investigator completed it by answering to the following: 'Assess the overall change in the severity of patient's illness, compared to start of study medication.'

Time frame:
Baseline to Last Visit or Early Discontinuation Visit in the 16-week Treatment Period
Reported as:
Mean · units on a scale
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit
units on a scalePlaceboBrivaracetam
Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit4.79 ± 1.145.00 ± 1.22
SecondaryChange From Baseline to the 16-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score2.98 ± 18.003.34 ± 19.06
SecondaryChange From Baseline to the 16-week Treatment Period in Emotional Well-being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Emotional Well-being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Emotional Well-being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score1.97 ± 19.292.84 ± 18.07
SecondaryChange From Baseline to the 16-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score2.28 ± 19.885.51 ± 18.55
SecondaryChange From Baseline to the 16-week Treatment Period in Overall Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Overall Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Overall Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score-0.48 ± 17.404.08 ± 19.23
SecondaryChange From Baseline to the 16-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score

The Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into 7 multi-item subscales: Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items), and a Health Status item. In addition to the 31 items of the QOLIE-31, the QOLIE-31-P contains 7 items asking the subjects to rate the degree of 'distress' related to the topic of each subscale (ie, distress items). The QOLIE-31-P also contains an item asking about the relative importance of each subscale topic (ie, prioritization item). The subscale scores, the total score and the Health Status item score were calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function.

Time frame:
Baseline to 16-week Treatment Period
Reported as:
Mean · units on a scale
Change From Baseline to the 16-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score
units on a scalePlaceboBrivaracetam
Change From Baseline to the 16-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score2.83 ± 27.21-0.24 ± 25.84

Adverse events

Collected over Adverse Events (AEs) were collected up to 24 weeks from Visit 1 (Week -4) to the Safety Visit (Week 20).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—9/121 (7.4%)40/121 (33.1%)
Brivaracetam—20/359 (5.6%)139/359 (38.7%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPlaceboBrivaracetam
ConvulsionNervous system disorders1/1217/359
Hepatitis BInfections and infestations1/1210/359
Pyelonephritis acuteInfections and infestations1/1210/359
DepressionPsychiatric disorders1/1211/359
TremorNervous system disorders1/1210/359
Ankle fractureInjury, poisoning and procedural complications1/1210/359
Face injuryInjury, poisoning and procedural complications1/1210/359
FallInjury, poisoning and procedural complications1/1210/359
Head injuryInjury, poisoning and procedural complications1/1210/359
Spinal fractureInjury, poisoning and procedural complications1/1210/359
Most frequent other events
Most frequent other events
EventPlaceboBrivaracetam
HeadacheNervous system disorders24/12152/359
SomnolenceNervous system disorders5/12140/359
NauseaGastrointestinal disorders11/12120/359
DizzinessNervous system disorders7/12131/359
FatigueGeneral disorders5/12127/359
NasopharyngitisInfections and infestations8/12114/359
Back painMusculoskeletal and connective tissue disorders8/12111/359

Baseline characteristics

Baseline characteristics refer to the Randomized Set (RS).

Age, Categorical
Age, Categorical(Participants)PlaceboBrivaracetamTotal Title
<=18 years358
Between 18 and 65 years116352468
>=65 years224
Age, Continuous
Age, Continuous(years)PlaceboBrivaracetamTotal Title
Mean36.5 ± 11.535.6 ± 11.535.85 ± 11.52
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBrivaracetamTotal Title
Female52178230
Male69181250
08

Study locations

63 sites
  • Graz, Austria
  • Innsbrick, Austria
  • Linz, Austria
  • Vienna, Austria
  • Wien, Austria
  • Brugge, Belgium
  • Godinne, Belgium
  • Leuven, Belgium
  • Montignies Sur Sambre, Belgium
  • Beroun, Czechia
  • Brno, Czechia
  • Ostrava Trebovice, Czechia
  • Praha 2, Czechia
  • Praha 5, Czechia
  • Zlin, Czechia
  • Berlin, Germany
  • Bernau, Germany
  • Bielefeld, Germany
  • Erlangen, Germany
  • Göttingen, Germany
  • Jena, Germany
  • München, Germany
  • Hong Kong, Hong Kong
  • Bangalore, India
  • Hyderabad, India
  • Mumbai, India
  • New Delhi, India
  • Pune Maharashtra, India
  • Tirupati, India
  • Bari, Italy
  • Milano, Italy
  • Pavia, Italy
  • Roma, Italy
  • Siena, Italy
  • Gwangju, Korea, Republic of
  • Seoul, Korea, Republic of
  • Bergen, Norway
  • Fredrikstad, Norway
  • Oslo, Norway
  • Sandvika, Norway
  • Trondheim, Norway
  • Kazan, Russian Federation
  • Moscow, Russian Federation
  • Samara, Russian Federation
  • St. Petersburg, Russian Federation
  • Yaroslavi, Russian Federation
  • Singapore, Singapore
  • Cape Town, South Africa
  • George, South Africa
  • Johannesburg, South Africa
  • Tygeberg, South Africa
  • Göteborg, Sweden
  • Stockholm, Sweden
  • Umea, Sweden
  • Taichung, Taiwan
  • Tainan, Taiwan
  • Taoyuan Hsien, Taiwan
  • Donetsk, Ukraine
  • Kharkov, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Odessa, Ukraine
  • Uzhgorod, Ukraine
09

References and documents

Publications

  • Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014 Jan;55(1):38-46. doi: 10.1111/epi.12391. Epub 2013 Oct 3. PubMed 24116853 ↗
  • Mukuria C, Young T, Keetharuth A, Borghs S, Brazier J. Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam. Qual Life Res. 2017 Mar;26(3):749-759. doi: 10.1007/s11136-016-1483-3. Epub 2016 Dec 21. PubMed 28004320 ↗
  • Bresnahan R, Panebianco M, Marson AG. Brivaracetam add-on therapy for drug-resistant epilepsy. Cochrane Database Syst Rev. 2022 Mar 14;3(3):CD011501. doi: 10.1002/14651858.CD011501.pub3. PubMed 35285519 ↗
  • Ben-Menachem E, Baulac M, Hong SB, Cleveland JM, Reichel C, Schulz AL, Wagener G, Brandt C. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial. Epilepsy Res. 2021 Feb;170:106526. doi: 10.1016/j.eplepsyres.2020.106526. Epub 2020 Dec 4. PubMed 33461041 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 8 years 4 months after primary completion. A results delay was requested in Feb 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2007
First posted
Jul 20, 2007
Start
Oct 2007
Primary completionActual
Nov 2008
CompletionActual
Dec 2008
Results delay requested
Feb 1, 2010
Results first posted
Mar 17, 2017
Last update
Apr 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00504881
Lead sponsor
UCB Pharma SA
Responsible party
Sponsor
First posted
Jul 20, 2007
Start date
Oct 2007
Primary completion
Nov 2008
Completion
Dec 2008
Results posted
Mar 17, 2017
Last update
Apr 3, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion